Redefining equity in the rare disease context Equity in rare and genetic disease clinical trials is both a scientific necessity and an ethical responsibility
Unlike patients with more common conditions, those living with rare diseases often face longer diagnostic journeys, fewer treatment options and limited access to specialty care and clinical research trials. With these challenges, it is critical that rare disease patients and families can benefit from medical innovation leading to potential treatments. Learn more about the tailored, patient-centric approaches advancing patient equity
Offered Free by: PPD
See All Resources from: PPD
